Teva Pharmaceutical Industries Ltd. agreed to pay the state of California $69 million in what California Attorney General Xavier Becerra Monday called the largest pay-for-delay settlement received by any state.
Ziopharm Oncology Inc., of Boston, said it entered into an agreement with existing investors for the exercise of previously issued warrants to purchase common stock in a private placement, being led by existing stockholder, MSD Partners LP, that is expected to result in gross proceeds of approximately $45 million.
Alvotech ehf, of Reykjavik, Iceland and Cipla Gulf FZ LLC, a wholly-owned subsidiary of Mumbai-based Cipla Ltd., said they have entered into an exclusive partnership for the commercialization of AVT-02, a MAb biosimilar to Humira (adalimumab, Abbvie Inc.), in select emerging markets.
Verastem Oncology Inc., of Boston, said it entered an exclusive licensing deal with Paris-based Sanofi SA to develop and commercialize Copiktra (duvelisib), an oral PI3K-delta/gamma inhibitor, for all oncology indications in Russia and CIS, Turkey, the Middle East and Africa.
Exopharm Ltd., of Melbourne, Australia, said it finalized an AU$4.44 million (US$3.03 million) share placement to new institutional and sophisticated investors.
Curza Global LLC, of Salt Lake City, received a $5.25 million investment from Novo Holdings Repair Impact Fund to support the advancement of its CZ-02 program that targets multidrug-resistant gram-negative infections.